Role of stereotactic body radiation therapy for hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 20, Issue 12, 2014, Pages 3100-3111

  Sanuki, Naoko ^a   Takeda, Atsuya ^a   Kunieda, Etsuo ^b  

^a Ofuna Chuo Hospital   (Japan)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Liver cirrhosis; Liver neoplasms; Radiation therapy; Stereotactic body radiation therapy

Indexed keywords

GADOXETIC ACID; SORAFENIB;

ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SURVEILLANCE; ECHOGRAPHY; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER METASTASIS; LIVER TRANSPLANTATION; LIVER TUMOR; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEREOTACTIC BODY RADIATION THERAPY; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; COMPLICATION; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIATION RESPONSE; RADIOSURGERY; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; RADIOSURGERY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84896921887     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i12.3100     Document Type: Article

References (72)

1. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-1259 [PMID: 16160134 DOI: 10.1001/jama.294.10.1255]
2. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74 [PMID: 20175034 DOI: 10.1055/s-0030-1247133]
3. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Ga-stroenterol 2009; 44 Suppl 19: 102-107 [PMID: 19148802 DOI: 10.1007/s00535-008-2251-0]
4. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vec-chia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008; 48: 137-145 [PMID: 18537177 DOI: 10.1002/hep.22312]
5. Izumi R, Shimizu K, Ii T, Yagi M, Matsui O, Nonomura A, Miyazaki I. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994; 106: 720-727 [PMID: 8119543]
6. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-928 [PMID: 2990661]
7. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-755 [PMID: 9731568 DOI: 10.1002/hep.510280322]
8. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38: 207-215 [PMID: 12673442 DOI: 10.1007/s005350300038]
9. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171 [PMID: 11981766 DOI: 10.1053/jhep.2002.33156]
10. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepato-cellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739 [PMID: 12049862 DOI: 10.1016/S0140-6736(02)08649-X]
11. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo) em-bolisation for unresectable hepatocellular carcinoma (Review). New York: John Wiley & Sons, Ltd., 2012
12. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-1156 [PMID: 16009687 DOI: 10.1136/gut.2004.045203]
13. Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Oza-ki K, Takeda T, Yoneda N, Notsumata K, Toya D, Tanaka N, Mitsui T. Ultraselective transcatheter arterial chemoemboli-zation with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007; 18: 365-376 [PMID: 17377182 DOI: 10.1016/ j.jvir.2006.12.004]
14. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-235 [PMID: 15830281 DOI: 10.1007/s00535-005-1566-3]
15. Sato T, Tateishi R, Yoshida H, Ohki T, Masuzaki R, Imamura J, Goto T, Kanai F, Obi S, Kato N, Shiina S, Kawabe T, Omata M. Ultrasound surveillance for early detection of hepatocel-lular carcinoma among patients with chronic hepatitis C. Hepatol Int 2009; 3: 544-550 [PMID: 19669240 DOI: 10.1007/ s12072-009-9145-y]
16. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gen-nari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699 [PMID: 8594428 DOI: 10.1056/ NEJM199603143341104]
17. de Villa V, Lo CM. Liver transplantation for hepatocellular carcinoma in Asia. Oncologist 2007; 12: 1321-1331 [PMID: 18055852 DOI: 10.1634/theoncologist.12-11-1321]
18. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]
19. Dawson LA. Overview: Where does radiation therapy fit in the spectrum of liver cancer local-regional therapies? Semin Radiat Oncol 2011; 21: 241-246 [PMID: 21939852 DOI: 10.1016/j.semradonc.2011.05.009]
20. Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. Int J Radiat Oncol Biol Phys 2012; 83: 895-900 [PMID: 22172906 DOI: 10.1016/ j.ijrobp.2011.08.032]
21. O'Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012; 18: 949-954 [PMID: 22467602 DOI: 10.1002/lt.23439]
22. Olsen CC, Welsh J, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, Gaspar LE, Schefter TE. Microscopic and macroscopic tumor and parenchymal effects of liver stereo-tactic body radiotherapy. Int J Radiat Oncol Biol Phys 2009; 73: 1414-1424 [PMID: 18990508]
23. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol 2010; 94: 1-11 [PMID: 20074823 DOI: 10.1016/j.radonc.2009.12.008]
24. Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995; 34: 861-870 [PMID: 7576756]
25. Dawson LA, Eccles C, Bissonnette JP, Brock KK. Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control. Int J Radiat Oncol Biol Phys 2005; 62: 1247-1252 [PMID: 15990028 DOI: 10.1016/ j.ijrobp.2005.03.072]
26. Eriguchi T, Takeda A, Sanuki N, Oku Y, Aoki Y, Shigematsu N, Kunieda E. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int J Radiat Oncol Biol Phys 2013; 85: 1006-1011 [PMID: 23102838 DOI: 10.1016/j.ijrobp.2012.09.012]
27. Facciuto ME, Singh MK, Rochon C, Sharma J, Gimenez C, Katta U, Moorthy CR, Bentley-Hibbert S, Rodriguez-Davalos M, Wolf DC. Stereotactic body radiation therapy in hepato-cellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol 2012; 105: 692-698 [PMID: 21960321 DOI: 10.1002/jso.22104]
28. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26: 657-664 [PMID: 18172187 DOI: 10.1200/ JCO.2007.14.3529]
29. Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K, Deluca J, Johnstone PA. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010; 12: 218-225 [PMID: 20231127]
30. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013; 31: 1631-1639 [PMID: 23547075 DOI: 10.1200/JCO.2012.44.1659]
31. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, Bae SH, Jung da H, Kim KB, Lee DH, Han CJ, Kim J, Park SC, Kim YH. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012; 118: 5424-5431 [PMID: 22570179 DOI: 10.1002/cncr.27533]
32. Choi BO, Jang HS, Kang KM, Lee SW, Kang YN, Chai GY, Choi IB. Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn J Clin Oncol 2006; 36: 154-158 [PMID: 16520355 DOI: 10.1093/jjco/hyi236]
33. Choi BO, Choi IB, Jang HS, Kang YN, Jang JS, Bae SH, Yoon SK, Chai GY, Kang KM. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer 2008; 8: 351 [PMID: 19038025 DOI: 10.1186/1471-2407-8-351]
34. Louis C, Dewas S, Mirabel X, Lacornerie T, Adenis A, Bono-deau F, Lartigau E. Stereotactic radiotherapy of hepatocel-lular carcinoma: preliminary results. Technol Cancer Res Treat 2010; 9: 479-487 [PMID: 20815419]
35. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010; 10: 475 [PMID: 20813065 DOI: 10.1186/1471-2407-10-475]
36. Seo YS, Kim MS, Yoo SY, Cho CK, Choi CW, Kim JH, Han CJ, Park SC, Lee BH, Kim YH, Lee DH. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 2010; 102: 209-214 [PMID: 20740576 DOI: 10.1002/jso.21593]
37. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes HR. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011; 81: e447-e453 [PMID: 21645977 DOI: 10.1016/j.ijrobp.2011.04.011]
38. Huang WY, Jen YM, Lee MS, Chang LP, Chen CM, Ko KH, Lin KT, Lin JC, Chao HL, Lin CS, Su YF, Fan CY, Chang YW. Stereotactic body radiation therapy in recurrent hepatocel-lular carcinoma. Int J Radiat Oncol Biol Phys 2012; 84: 355-361 [PMID: 22342300 DOI: 10.1016/j.ijrobp.2011.11.058]
39. Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Naeshiro N, Ono A, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Ishikawa M, Kakizawa H, Kenjo M, Takahashi S, Awai K, Nagata Y, Chayama K. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol 2013; 28: 530-536 [PMID: 23216217 DOI: 10.1111/jgh.12087]
40. Bae SH, Kim MS, Cho CK, Kim KB, Lee DH, Han CJ, Park SC, Kim YH. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci 2013; 28: 213-219 [PMID: 23400333 DOI: 10.3346/jkms.2013.28.2.213]
41. Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, Deng XW, Huang XY, Liu MZ. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/ or inferior vena cava tumor thrombosis. PLoS One 2013; 8: e63864 [PMID: 23737955 DOI: 10.1371/journal.pone.0063864]
42. Fuss M, Thomas CR. Stereotactic body radiation therapy: an ablative treatment option for primary and secondary liver tumors. Ann Surg Oncol 2004; 11: 130-138 [PMID: 14761915]
43. Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, Iwabuchi S, Kunieda E. Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients. Acta Oncol 2014; 53: 399-404 [PMID: 23962244 DOI: 10.3109/0284186X.2013.820342]
44. Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Ten Haken RK, Knol J, Dawson LA, Pan C, Lawrence TS. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery foxuridine for unresectable intra-hepatic malignancies. J Clin Oncol 2005; 23: 8739-8747 [PMID: 16314634 DOI: 10.1200/JCO.2005.01.5354]
45. Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol 2006; 45: 856-864 [PMID: 16982550 DOI: 10.1080/02841860600936369]
46. Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, Kokubu S, Saigenji K. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. J Gastro-enterol 2008; 43: 71-78 [PMID: 18297439 DOI: 10.1007/s00535-007-2123-z]
47. Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Höss A, Schlegel W, Wannenmacher MF. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001; 19: 164-170 [PMID: 11134209]
48. Wulf J, Hädinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 2001; 177: 645-655 [PMID: 11789403]
49. Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN, Levendag PC. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 2006; 45: 831-837 [PMID: 16982547 DOI: 10.1080/02841860600897934]
50. Iwata H, Shibamoto Y, Hashizume C, Mori Y, Kobayashi T, Hayashi N, Kosaki K, Ishikawa T, Kuzuya T, Utsunomiya S. Hypofractionated stereotactic body radiotherapy for primary and metastatic liver tumors using the novalis image-guided system: preliminary results regarding effcacy and toxicity. Technol Cancer Res Treat 2010; 9: 619-627 [PMID: 21070084]
51. Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, Koong AC. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010; 78: 486-493 [PMID: 20350791 DOI: 10.1016/j.ijrobp.2009.08.020]
52. Gunvén P, Jonas E, Blomgren H, Rutkowska E, Karlsson K, Lax I, Levitt S. Undetectable late hepatic sequelae after hypofractionated stereotactic radiotherapy for liver tumors. Med Oncol 2011; 28: 958-965 [PMID: 20490719 DOI: 10.1007/ s12032-010-9567-3]
53. Dewas S, Bibault JE, Mirabel X, Fumagalli I, Kramar A, Jar-raya H, Lacornerie T, Dewas-Vautravers C, Lartigau E. Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy. Radiat Oncol 2012; 7: 166 [PMID: 23050794 DOI: 10.1186/1748-717X-7-166]
54. Ibarra RA, Rojas D, Snyder L, Yao M, Fabien J, Milano M, Katz A, Goodman K, Stephans K, El-Gazzaz G, Aucejo F, Miller C, Fung J, Lo S, Machtay M, Sanabria JR. Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. Acta Oncol 2012; 51: 575-583 [PMID: 22263926 DOI: 10.3109/0284186X.2011.652736]
55. van Laarhoven HW, Kaanders JH, Lok J, Peeters WJ, Rijken PF, Wiering B, Ruers TJ, Punt CJ, Heerschap A, van der Kogel AJ. Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. Int J Ra-diat Oncol Biol Phys 2006; 64: 473-482 [PMID: 16242253 DOI: 10.1016/j.ijrobp.2005.07.982]
56. Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T. Stereotactic body radiotherapy (SBRT) for oligometa-static lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol 2011; 101: 255-259 [PMID: 21641064 DOI: 10.1016/ j.radonc.2011.05.033]
57. Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, Mizuno T, Yashiro K, Nisimura S, Kunieda E. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 372-379 [PMID: 23927053 DOI: 10.1111/jgh.12350]
58. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 667-685 [PMID: 20633193 DOI: 10.1111/j.1872-034X.2010.00673.x]
59. Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, Ten Haken RK. Radiation-associated liver injury. Int J Ra-diat Oncol Biol Phys 2010; 76: S94-100 [PMID: 20171524 DOI: 10.1016/j.ijrobp.2009.06.092]
60. Xu ZY, Liang SX, Zhu J, Zhu XD, Zhao JD, Lu HJ, Yang YL, Chen L, Wang AY, Fu XL, Jiang GL. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 2006; 65: 189-195 [PMID: 16542787]
61. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965; 93: 200-208 [PMID: 14243011]
62. Reed GB, Cox AJ. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol 1966; 48: 597-611 [PMID: 5327788]
63. Herfarth KK, Hof H, Bahner ML, Lohr F, Höss A, van Kaick G, Wannenmacher M, Debus J. Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys 2003; 57: 444-451 [PMID: 12957256]
64. Sanuki-Fujimoto N, Takeda A, Ohashi T, Kunieda E, Iwabu-chi S, Takatsuka K, Koike N, Shigematsu N. CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function. Br J Radiol 2010; 83: 1063-1071 [PMID: 21088090 DOI: 10.1259/bjr/74105551]
65. Takeda A, Oku Y, Sanuki N, Kunieda E, Koike N, Aoki Y, Ohashi T, Iwabuchi S, Takatsuka K, Takeda T, Sugawara A. Dose volume histogram analysis of focal liver reaction in follow-up multiphasic CT following stereotactic body radiotherapy for small hepatocellular carcinoma. Radiother Oncol 2012; 104: 374-378 [PMID: 22248506 DOI: 10.1016/ j.radonc.2011.12.008]
66. Asayama Y, Tajima T, Nishie A, Ishigami K, Kakihara D, Nakayama T, Okamoto D, Fujita N, Aishima S, Shirabe K, Honda H. Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: radiologic-pathologic correlation with special reference to bile production. Eur J Radiol 2011; 80: e243-e248 [PMID: 21109378 DOI: 10.1016/j.ejrad.2010.10.032]
67. Tamada T, Ito K, Sone T, Kanki A, Sato T, Higashi H. Gd-EOB-DTPA enhanced MR imaging: evaluation of biliary and renal excretion in normal and cirrhotic livers. Eur J Radiol 2011; 80: e207-e211 [PMID: 20869827 DOI: 10.1016/ j.ejrad.2010.08.033]
68. Sanuki N, Takeda A, Mizuno T, Oku Y, Eriguchi T, Iwabu-chi S, Kunieda E. Tumor response on CT following hypofrac-tionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. AJR Am J Roentgenol 2013; 201: W812-W820 [PMID: 24261388]
69. Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, Abei M, Kawaguchi A, Hayashi Y, Ookawa A, Hashii H, Kanemoto A, Moritake T, Tohno E, Tsuboi K, Sakae T, Sakurai H. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys 2011; 81: 1039-1045 [PMID: 20888707 DOI: 10.1016/j.ijrobp.2010.07.015]
70. Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizu-moto M, Abei M, Shoda J, Thono E, Tsuboi K, Tokuuye K. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009; 74: 831-836 [PMID: 19304408 DOI: 10.1016/ j.ijrobp.2008.10.073]
71. Skinner HD, Hong TS, Krishnan S. Charged-particle therapy for hepatocellular carcinoma. Semin Radiat Oncol 2011; 21: 278-286 [PMID: 21939857 DOI: 10.1016/j.semradonc.2011.05.007]
72. Zhang W, Zhang J, Yan W, You G, Bao Z, Li S, Kang C, Jiang C, You Y, Zhang Y, Chen CC, Song SW, Jiang T. Whole-genome microRNA expression profiling identifies a 5-mi-croRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer 2013; 119: 814-824 [PMID: 22990979 DOI: 10.1002/cncr.27826]